Loading…
← CockpitCompetitor Analysis › NIVABUPA.NS Niva Bupa Health Insurance CompanyOpen in the cockpit ↗

Niva Bupa Health Insurance CompanyNIVABUPA.NSCompetitor analysis, valuation and peers

India · INR·Financials›Life/Health Insurance

Health insurance joint venture between UK's Bupa and an Indian promoter group, selling individual and group health policies.

Momentum weak 30
Mkt cap
$1.46B
US dollars, full cap
Free float
25%
of shares outstanding
$/day
$1.14M
20-day average traded
P/B
3.55×
price to book
ROE
13.9%
delivered
Implied ROE
32.5%
what the price asks
Next earnings
83 days
9 Feb 2027
Close · INR₹73.80
1D-2.4%
1W-4.1%
1M-3.2%
3M-11.9%
6M-8.9%
YTD-2.1%
1Y-3.5%
ATR %3.3%
Beta0.31
52w lowhigh19.3% off high

What Niva Bupa Health Insurance does

Health insurance joint venture between UK's Bupa and an Indian promoter group, selling individual and group health policies.

Collects premiums on health policies and pays out hospital-bill claims, so what it keeps depends on how claims and selling costs compare with premiums charged. Policies are sold through agents, brokers and bank partnerships. It was called Max Bupa until 2021 and listed on the stock market in 2024.

Products and services

  • Retail health insurance
  • Group health insurance
  • Wellness/preventive care add-ons

Customers

  • Individual policyholders
  • Corporate group insurance buyers

Where it sits in the supply chain

  • Financial services/insurance
  • Health insurance
  • Retail & group health insurance

What could go right

  • Rising health insurance penetration in India
  • Premium growth from medical inflation

What could go wrong

  • Claims ratio/medical cost inflation risk
  • Intense competition from Star Health and multi-line insurers

Moat: narrow (brand, distribution). Bupa's global health-insurance expertise combined with a growing Indian distribution network.

Headquarters: New Delhi, India · Founded: 2008

Named competitors

Niva Bupa Health Insurance at a glance

Size Niva Bupa Health Insurance (NIVABUPA.NS) is an India Financials company (Life/Health Insurance) with a market value of $1.46B, the 486th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹73.80 on 18 Nov 2026.

Performance Over six months the shares fell 8.9%, against +0.7% for the median peer and +3.8% for the India market (cap-weighted) — 6th lowest of 17 in its peer set.

Growth Revenue grew 58.2% over the last twelve months (peer median +17.3%); the operating margin is 7.5% (peer median 6.0%).

Valuation It trades at 3.55× book value against a peer median of 1.08× (5th most expensive of 17).

Price implies The share price implies a return on equity of about 32.5%; Niva Bupa Health Insurance delivers 13.9%, so the price asks more than the business earns today.

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 100NIVABUPA.NS 91
Six months, rebased to 100: Niva Bupa Health Insurance against the median of its 16 peers (local-currency closes).

Niva Bupa Health Insurance financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹81.1B₹84.6B₹63.3B₹43.3B₹32.3B
Revenue growth—+34%+46%+34%—
Net income₹5.31B₹3.66B₹2.03B₹818M₹85.1M
Free cash flown/a₹14.8B₹20.2B₹7.53B₹7.15B
Capital expendituren/a₹486M₹414M₹330M₹378M
Total debt₹2.68B₹3.54B₹3.52B₹2.50B₹3.30B

Quarterly statements and history in the cockpit →

Niva Bupa Health Insurance competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-20%-10%0%+10%NBG6CANHLIFE085620088350CLOVBHF0376002423PRVA71575859STARHEALTHELF2905MFSLCGFNIVABUPA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Niva Bupa Health Insurance is the large dot.

Fundamentals: return on equity against price-to-book

-100%-50%0%00×2.50×50×7.50×NBG6CANHLIFE085620088350CLOVBHFPRVASTARHEALTHELF2905MFSLCGFNIVABUPA.NSReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Niva Bupa Health Insurance is the large dot.

Capital: ROE delivered against the ROE the price implies

-100%-50%0%50%-100%0%NBG6CANHLIFE085620CLOVPRVA2905MFSLCGFNIVABUPA.NSROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. Niva Bupa Health Insurance is the large dot.

Niva Bupa Health Insurance competitors and peer comparison

Head to head with its named competitors (NIVABUPA.NS vs STARHEALTH.NS vs ICICIGI.NS)
CompanyMarket cap6M returnRevenue growthROEPrice / bookImplied ROE
Niva Bupa Health Insurance NIVABUPA.NS$1.46B-9%+58%14%3.55×32.5%
Star Health & Allied Insurance STARHEALTH.NS$3.53B+8%+21%12%3.16×47.6%
ICICI Lombard General Insurance ICICIGI.NS$8.78B-10%+14%15%4.37×54.2%

How Niva Bupa Health Insurance compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Niva Bupa Health Insurance against its 16 peers (data as of 18 Nov 2026)
MeasureNIVABUPA.NSPeer medianRank in peer set
1-month return-3.2%-0.7%7th lowest of 17
6-month return-8.9%+0.7%6th lowest of 17
Return on equity13.9%6.2%2nd highest of 17
Price / book3.55×1.08×5th most expensive of 17
Trailing P/E25.8×17.0×8th most expensive of 16
ROE the price implies32.5%6.8%5th most demanding of 17
ROE delivered13.9%6.2%2nd highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
Niva Bupa Health Insurance NIVABUPA.NSIndia$1.46B-9%+58%14%3.55×32.5%13.9%
Nuernberger Beteiligungs NBG6.DEGermany$1.55B+2%-1%5%1.58×6.1%5.1%
Canara HSBC Life Insurance CANHLIFE.NSIndia$1.29B-8%+17%8%7.36×50.5%8.2%
Mirae Asset Life Insurance 085620.KSSouth Korea$1.70B+19%+152%2%1.06×5.8%1.8%
Hanwha Life 088350.KSSouth Korea$2.09B-33%+20%5%0.23×3.8%4.6%
Clover Health Investments CLOVUnited States$2.21B+16%+54%3%5.31×81.1%3.4%
Brighthouse Financial BHFUnited States$2.42B-33%-9%12%0.48×6.0%12.0%
Yunfeng Financial 0376.HKHong Kong$872M-24%+21%7%0.53×7.4%6.7%
COFCO Capital 002423.SZChina$3.08B-7%-31%6%0.83×6.1%5.6%
Privia Health PRVAUnited States$3.14B+6%+19%5%3.85×25.7%4.6%
Lifenet Insurance 7157.TJapan$652M-28%+11%8%1.11×7.0%7.6%
Farglory Life Insurance 5859.TWOTaiwan$614M-1%-48%7%0.22×1.7%7.1%
Star Health & Allied Insurance STARHEALTH.NSIndia$3.53B+8%+21%12%3.16×47.6%11.7%
E-L Financial ELF.TOCanada$4.65B+15%+32%20%0.69×6.5%20.2%
Mercuries & Associates 2905.TWTaiwan$456M+11%-43%-118%0.56×2.7%-117.8%
Max Financial Services MFSL.NSIndia$5.25B-12%+18%3%8.53×87.5%3.3%
Challenger CGF.AXAustralia$5.26B+28%-25%13%1.95×15.5%13.3%

Questions

Who are Niva Bupa Health Insurance's main competitors?
Named competitors: Star Health & Allied Insurance (STARHEALTH.NS), ICICI Lombard General Insurance (ICICIGI.NS). The cockpit's measured peer set (industry) also includes Nuernberger Beteiligungs (NBG6.DE), Canara HSBC Life Insurance (CANHLIFE.NS), Mirae Asset Life Insurance (085620.KS), Hanwha Life (088350.KS), Clover Health Investments (CLOV), Brighthouse Financial (BHF).
Is Niva Bupa Health Insurance expensive compared with its peers?
On price / book it trades at 3.55× against a peer median of 1.08×, 5th most expensive of 17 in its peer set. The share price implies a return on equity of about 32.5%; Niva Bupa Health Insurance delivers 13.9%, so the price asks more than the business earns today.
How has Niva Bupa Health Insurance stock performed?
Over six months to 18 Nov 2026 the shares returned -8.9% against +0.7% for the median peer; over one year -3.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.